Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)
about
Current progress and challenges in HIV gene therapyEfficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyHomologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialHIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengePhase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPrime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsContinued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.A Recombinant Adenovirus Encoding Multiple HIV-1 Epitopes Induces Stronger CD4(+) T cell Responses than a DNA Vaccine in Mice.Mixture models for single-cell assays with applications to vaccine studiesHIV-specific CD4 T cells and immune control of viral replication.Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria.Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls.A novel HIV vaccine targeting the protease cleavage sites.Progress in respiratory virus vaccine development
P2860
Q29393523-4B6461C5-977E-468F-A5CE-D0C1AE0F854FQ30578618-2CE69AC6-2B4C-4613-9084-DDC0AD02F8EBQ30620607-AF4FEC65-86B6-4B28-A58A-7A4192166090Q34023588-D222202D-A005-49CB-AE17-45D404DF6FE3Q34170122-0D5DC4E6-6BF3-4D55-8324-39D2530FFA58Q34229329-09255861-BF28-49F4-8565-B2F5D11C63E8Q34240204-115DE4B9-FFBD-4AFB-B32F-F6D16479E5A6Q34263835-274EC6A0-691E-4022-AE9E-97B56A1EF2F2Q34332340-68227D70-44A8-438F-9C42-C1D39BD4FCEBQ34606356-A2C8BE2A-0A49-4F08-AC2B-0DC6EB7D2ED0Q34663554-E76BFF4A-A8D5-440F-8935-DE6590F58952Q34789269-98D5A934-47F8-4377-B62F-CFC06ACE96F9Q35076828-48F3CA0D-3F2B-4421-8AA6-B87BC8786D1DQ35118834-1C3341BC-F195-4019-9F50-A729BD4A2A3AQ35140001-9376CAC4-0FE5-4871-971F-D795C635AD04Q35160124-A7A7D497-5AEE-41F5-9750-8C4A358D1D90Q35234257-431870DF-C9A8-44A6-B9BB-ABA56F49C523Q35344875-70BDCAE5-AE12-4DD9-BC2C-544B91D462D3Q35388181-862381A9-BABC-4C7B-B22C-8E04172464CAQ35741984-A0F0F24D-2C08-4104-9419-0D29DA236463Q35762443-C1EBB6DD-A5B6-46A4-9105-1AB627CA3AA3Q35774494-73B95735-2F5D-43C8-9947-51869D533BDFQ36097352-BE76B971-3ECF-4505-A94A-1188DD401AD8Q36113141-AE2620CE-6C67-4913-975A-DA2995F67B29Q36192765-48640FDC-B34C-444F-8FEB-D91E88196262Q36474557-EA226065-A1A1-42EF-A311-8EC4BF004178Q36956883-48DC29A2-F8A9-413B-9600-63621FA50CC3Q37390047-50B4D272-A9AE-4D6C-B8C6-CD70121909D3Q37866624-CCE2C0F3-EB4B-4D24-89B9-9010F6BDCDA6Q37924616-FE57A2D9-E4C2-422A-AC59-3F43233814CBQ38295771-CA703D0C-914D-4464-900B-A12DC543A407Q40047295-D819E8C0-3B6D-43A8-8D92-05B3499ABB0AQ56894869-79DAF2F6-5B66-41A0-AFD9-E972B1414F88
P2860
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@ast
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@en
type
label
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@ast
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@en
prefLabel
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@ast
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@en
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of a ...... ized clinical trial (HVTN 054)
@en
P2093
Cecilia Morgan
Georgia D Tomaras
NIAID HIV Vaccine Trials Network
Nina Russell
Stephen C De Rosa
Zoe Moodie
P2860
P304
P356
10.1371/JOURNAL.PONE.0013579
P407
P577
2010-10-27T00:00:00Z